Repeated injection of ␣-galactosylceramide, an agonistic ligand for natural killer T (NKT) cells, results in long-term unresponsiveness or anergy, which severely limits its clinical application. However, the molecular mechanisms leading to NKT anergy induction remain unclear. We show here that the decreased IFN-␥ production and failed tumor rejection observed in anergized NKT cells are rescued by Cbl-b deficiency. Cbl-b E3 ligase activity is critical for the anergy induction, as revealed by the similarity between Cbl-b ؊/؊ and its RING finger mutant NKT cells. Cbl-b binds and promotes monoubiquitination to CARMA1, a critical signaling molecule in NFB activation. Ubiquitin conjugation to CARMA1 disrupts its complex formation with Bcl10 without affecting its protein stability. In addition, CARMA1 ؊/؊ NKT cells are defective in IFN-␥ production. The study identifies an important signaling pathway linking Cblb-induced monoubiquitination to NFB activation in NKT cell anergy induction, which may help design approaches for human cancer therapy. The marine sponge-derived ␣-GalCer has been widely used for the study of NKT cells both in vitro and in vivo and is a promising candidate for NKT cell-mediated therapies. However, it has been reported that injection of ␣-GalCer into mice results in the hypo-or unresponsiveness of NKT cells to restimulation in vivo and in vitro (6-9). The unresponsiveness is long-lasting and can be reversed by the addition of exogenous IL-2, thus resembling conventional anergic CD4 ϩ T cells, which may limit the clinical application of ␣-GalCer (10). However, the molecular mechanisms underlying NKT cell unresponsiveness or anergy remain unclear.
E3 ubiquitin ligase ͉ immune tolerance ͉ NFkB signaling ͉ signal transduction N atural killer T (NKT) cells are a distinct subset of lymphocytes that are characterized by the cell surface expression of a single invariant T-cell receptor (TCR) ␣ chain encoded by V␣14-J␣18 paired preferentially with diverse V␤8.2 rearrangement in mice and NK cell markers (1, 2) . The activation of NKT cells is initiated by the engagement of the NKT receptor with glycolipid antigens such as ␣-GalCer presented by the MHC class I-like molecule CD1d, which leads to the rapid production of cytokines such as IFN-␥, IL-4, and the regulation of many other types of cells. The importance of NKT cells is reflected in their involvement in tumor surveillance, tissue transplantation, autoimmune diseases (3) , and in allergic asthma (4, 5) .
The marine sponge-derived ␣-GalCer has been widely used for the study of NKT cells both in vitro and in vivo and is a promising candidate for NKT cell-mediated therapies. However, it has been reported that injection of ␣-GalCer into mice results in the hypo-or unresponsiveness of NKT cells to restimulation in vivo and in vitro (6) (7) (8) (9) . The unresponsiveness is long-lasting and can be reversed by the addition of exogenous IL-2, thus resembling conventional anergic CD4 ϩ T cells, which may limit the clinical application of ␣-GalCer (10) . However, the molecular mechanisms underlying NKT cell unresponsiveness or anergy remain unclear.
It was shown that Cbl-b is up-regulated during anergy induction of conventional T cells, and it controls the tolerigenic process by modulating the critical signaling molecules like phospholipase-␥1 (PLC-␥1) (11, 12) , thus implicating protein ubiquitination pathway to T-cell tolerance. To address whether Cbl-b plays a role in the anergy induction of NKT cells, we established mouse models of NKT cell anergy induction and found that Cbl-b deficiency reverse the suppressed IFN-␥ production and failed tumor eradication of anergized NKT cells. Further molecular investigation identifies a protein degradationindependent pathway in which Cbl-b targets the monoubiquitination of CARMA1, a critical adaptor in NFB activation. The results would be of critical importance in the therapeutic development of ␣-GalCer-based therapy to fight cancer or autoimmune diseases.
Results
Cbl-b in NKT Cell Anergy Induction. To examine whether Cbl-b is involved in NKT cell anergy induction, we first compared the protein expression of Cbl-b in NKT cells from control and ␣-GalCer-tolerized mice. Both the protein amounts and the mRNA levels of Cbl-b were augmented in ␣-GalCer-pretreated NKT cells ( Fig. 1 A and B and Fig. S1 A) . The suppressed IFN-␥ production in wild-type anergic NKT cells was largely rescued by Cbl-b deficiency (Fig. 1C) , whereas the IL-4 concentrations were comparable between wild-type and Cbl-b Ϫ/Ϫ NKT cells. However, the antigen receptor numbers of NKT cells were not overtly changed in Cbl-b Ϫ/Ϫ NKT cells in control and ␣-GalCerpretreated mice (Fig. S1B ). In addition, Cbl-b deficiency did not rescue the proliferative inhibition of anergic NKT cells ( Fig. 1D and Fig. S1C ), even upon repeated experiments. Furthermore, ablation of c-Cbl, a close homolog of Cbl-b, did not affect the suppressed IFN-␥ production of anergy NKT cells (Fig. 1E) . The results suggest that Cbl-b is selectively involved in the anergic induction of NKT cells, particularly the IFN-␥ production.
In Vivo Function of Cbl-b During NKT Tolerance Induction. We next investigated the contribution of Cbl-b in NKT cell anergy induction in vivo. The reduced serum IFN-␥ concentrations in ␣-GalCer-tolerized mice were recovered to a larger degree in Cbl-b Ϫ/Ϫ mice ( Fig. 2A, Left) , even after 4 h of ␣-GalCer reboost, and the rescue became more obvious at the 24 h time point. However, Cbl-b had no effect on the serum IL-4 concentrations in control or ␣-GalCer-tolerized mice (Fig. 2 A, Right) . We next examined the downstream effector cells in those mice. The suppression of the expression of activation markers and IFN-␥ production in NK cells, CTLs, or DCs from ␣-GalCer-tolerized mice were almost completed released in Cbl-b Ϫ/Ϫ mice ( Fig. 2 B and C and Fig. S2 ).
Cbl-b E3 Ligase Activity in NKT-Involved Tumor Metastasis. To further understand whether Cbl-b-mediated NKT cell anergy induction plays a biological role in vivo, we adopted the lung tumor metastasis model in which B16 melanoma cells were injected into control and ␣-GalCer-tolerized mice, followed by the reboost of ␣-GalCer to activate NKT cells. The numbers of tumor modules in the lung were markedly reduced in ␣-GalCer-unpretreated wild-type and Cbl-b Ϫ/Ϫ mice upon ␣-GalCer reboost (Fig. 3A) . However, ␣-GalCer-tolerized wild-type mice displayed decreased capability in preventing tumor metastasis. In a sharp contrast, Cbl-b Ϫ/Ϫ mice were still capable of blocking tumor formation in the lung event upon ␣-GalCer tolerance induction.
To understand the importance of the Cbl-b E3 ligase activity, we analyzed the Cbl-b knockin mice containing a mutation in the critical cysteine 373 of the RING finger domain to alanine (C373A) (13) . Cbl-b C373A mutant knockin mice did not change the NKT cell populations in the spleen (Fig. S3 ) and other various organs (data not shown). Compared with the littermate controls, Cbl-b C373A mutant NKT cells exhibited increased IFN-␥ production (Fig. 3B ). Like Cbl-b Ϫ/Ϫ NKT cells, the IFN-␥ production in Cbl-b C373A mutant mice were not suppressed under ␣-GalCer-induced tolerizing conditions (Fig. 3C ). More importantly, the Cbl-b C373A mutant mice showed similar ability in inhibiting tumor metastasis as Cbl-b Ϫ/Ϫ mice under ␣-GalCer-tolerizing conditions (Fig. 3D) . The results clearly suggest that the E3 ligase activity is required for the suppressed IFN-␥ production of anergic NKT cells.
Mechanisms of Cbl-b-Mediated NKT Cell Anergy. We then established a system of in vitro ionomycin-induced anergy using cultured human NKT cells (Fig. S4) . By using this system, we next attempted to investigate the intracellular signaling events involved in Cbl-b-mediated NKT cell anergy induction. It seems that the phosphorylation status of TCR, Zap-70, Akt, and Erk1/2 is not altered by ionomycin pretreatment (Fig. 4A and Fig. S5 A and B) . However, the phosphorylation of PLC-␥1 is reduced in ionomycin-anergized NKT cells. More remarkably, the IB␣ degradation is almost completely inhibited in ionomycin-pretreated human NKT cells (Fig. 4B ). To address whether Cbl-b is involved in the degradation of IB␣ during NKT tolerance induction, we used the Cbl-b siRNA knocked down cells and found that reduction of Cbl-b expression resulted in the recovery of IB␣ degradation (Fig. 4C) . To recapitulate the finding in human NKT cells in mouse primary NKT cells, we next assessed the phosphorylation status of the p65 form of NFB. Phosphorylation of p65 was decreased in wild-type NKT cells from ␣-GalCer-tolerized mice, whereas such reduction was largely restored in Cbl-b Ϫ/Ϫ NKT cells under the same tolerizing conditions (Fig. 4D) . Cbl-b deficiency did not alter the phosphorylation status of Erk1/2 proteins. In addition, Cbl-b C373A mutation resulted in increased degradation of IB␣ in CD4 ϩ T cells and NKT cells upon stimulation (Fig. S5 C and D) . The importance of NFB signaling pathway in NKT cell tolerance (Fig. 4E) , a phenomenon similar to anergized NKT cells. The results suggest that Cbl-b is involved in the regulation of intracellular signal transduction during NKT anergy induction, and most likely, the NFB signaling pathway.
CARMA1 as a Target for Cbl-b in NKT Cells. To dissect the detailed molecular mechanisms by which Cbl-b regulates NFB signaling, we searched its potential binding partners by performing coimmunoprecipitation assay. We found that Cbl-b was strongly copurified with CARMA1, less efficiently with TAK1, but not with PDK1, Bcl10, NEMO, and PKC (Fig. S6) . The interaction seemed to be specific, since the coprecipitation of Cbl-b was dependent on the expression of CARMA1 (Fig. 5A) , and endogenous interaction occurred in Jurkat T cells, which was even enhanced by TCR stimulation (Fig. 5B) . We next examined whether CARMA1 is a target for Cbl-b-promoted ubiquitination. Interestingly, Cbl-b only induced the ubiquitin conjugation to CARMA1 in a very low molecular weight form, which was estimated as the addition of a single ubiquitin, but not in the high molecular weight form (Fig. 5C ). The effect of Cbl-b on CARMA1 monoubiquitination was largely compromised by the RING finger mutation (Fig. 5C) . We also expressed wild-type ubiquitin or its lysine-less mutant and the ubiquitinated CARMA1 migrated at the same position in both samples, which displayed slight upshift compared with the unubiquitinated form (Fig. S7) . The effect of Cbl-b on CARMA1 monoubiquitination was examined in human NKT cells and Cbl-b siRNA-mediated knockdown abrogated ubiquitin conjugation to CARMA1 (Fig. 5D) .
The effect of Cbl-b on the protein stability of CARMA1 was also examined in mouse T cells and human NKT cells, and Cbl-b deficiency or up-regulation via ionomycin-treatment did not obviously affect the protein amounts of CARMA1 under either resting, stimulated, or ionomycin-tolerized conditions (Fig. S8) . CARMA1 directly associates with Bcl10 to transduce NFB signaling (14) . We then analyzed whether monoubiquitination of CARMA1 affects its binding to Bcl10 in human NKT cells upon anergy induction. The CARMA1-Bcl10 association was observed in TCR-stimulated human NKT cells (Fig. 5E) . However, such interaction was markedly reduced in ionomycin-pretreated NKT cells. To further obtain the genetic evidence that CARMA1 is important for NKT cell function, we examined the NKT cells from CARMA1 Ϫ/Ϫ mice (15) . Ablation of CARMA1 did not affect the NKT cell populations in the spleen (Fig. S9) . However, CARMA1
Ϫ/Ϫ NKT cells produced only minute amounts of IFN-␥, with only a slight effect on IL-4 production (Fig. 5F ). The data collectively suggest that Cbl-b targets CARMA1 for monoubiquitination, which in turn affects the downstream signaling leading to IFN-␥ production in NKT cells.
Discussion
Previous studies have demonstrated that Cbl-b controls the anergy induction of conventional CD4 ϩ and CD8 ϩ T cells, in which Cbl-b targets the ubiquitination of critical signaling mol- ecules such as PLC-␥1 and PKC, modulating their phoshphorylation status and/or protein stability in these cells (11, 12) . One clear difference is that Cbl-b is involved in both the proliferative inhibition and suppressed IL-2 production of anergic conventional T cells, while it affects only IFN-␥ production, but not the proliferation events of anergic NKT cells. Indeed, even though we observed similar decrease of PLC-␥1 phosphorylation in both cell types under ionomycin-treated conditions, Cbl-b Ϫ/Ϫ NKT cells displayed a marked augment of NFB activation, a phenomenon that was not previously observed in anergized Cbl-b Ϫ/Ϫ conventional T cells. This difference suggests that Cbl-b may play distinctive roles in the anergy induction between conventional and NKT cells.
Cbl proteins act as an E3 ligase by recruiting both E2-ubiquitin complex via its RING domain and the substrate(s) through its protein-interacting domains (16) . A number of signaling molecules were screened for potential substrates and CARMA1 was identified to be a strong binding partner for Cbl-b both in overexpressed and normal cells. Interestingly, Cbl-b promotes monoubiquitination of CARMA1 and does not affect its protein stability. It is possible that longer stimulation of NKT cells may lead to Cbl-b-mediated degradation of CARMA1. However, it seems that conjugation of CARMA1 with a single ubiquitin molecule mainly interferes with its association of Bcl10, a downstream transducer and a binding partner of the CARMA1-Bcl10-MALT1 (CBM) signaling complex (14) . Previous studies have shown that this complex is subjected to regulation via membrane targeting to the immunological synapse or via PKCinduced phosphorylation of CARMA1 (17) (18) (19) . It is not clear yet whether the monoubiquitination of CARMA1 causes a structural hindrance for the interaction of Bcl10, or affects its phosphorylation or intracellular translocation, that in turn indirectly modulates CARMA1-Bcl10 complex formation. In any case, the present study identifies a unique regulatory mechanism of CBM complex via Cbl-b-induced monoubiquitination.
CARMA1 is essential for TCR-and BCR-mediated NFB activation, lymphocyte proliferation, and cytokine production (15) . However, whether it is involved in function of NKT cells was not known. Previous reports indicated that blockade of NFB pathway signaling affect NKT cell development and loss of IKK2 induces downregulation of cytokines (20, 21) . Here, we found that CARMA1 deficiency does not overtly change the proportion of peripheral mature NKT cells. However, the IFN-␥ production is drastically reduced in CARMA1 Ϫ/Ϫ NKT cells in response to ␣-GalCer stimulation, whereas the effect on IL-4 production is rather moderate. The notion that CARMA1-mediated pathway is important for IFN-␥ production is further substantiated by the observation from IKK inhibitor-treated NKT cells, that displayed similar effects on IFN-␥ vs. IL-4 production. Interestingly, this unbalanced IFN-␥:IL-4 ratio in CARMA1 Ϫ/Ϫ or IKK inhibitor-treated NKT cells mimics the cytokine profile of anergized NKT cells. Taken all of the evidence together, the study suggests that CARMA1-mediated downstream activation of IKK complex is essential for both normal and anergic NKT cell activation. Further studies will address whether its binding partners Bcl10 or MALT1 function in a similar fashion. per well) from CARMA1 Ϫ/Ϫ mice were stimulated with ␣-GalCer (100 ng/mL), and cytokine production was measured. Results in F are means Ϯ SEM, and asterisk indicates P Ͻ 0.05 compared with WT or littermate control (Mann-Whitney U test).
